Nontoxic and renewable metal–organic framework based on α-cyclodextrin with efficient drug delivery

Sha, Jingquan; Zhong, Xinghua; Wu, Lian-He; Liu, Guodong; Sheng, Ning

doi:10.1039/c6ra16549d

Cited by 58 publications

(56 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This method was a pioneering step in the synthesis of α-CD-MOFs and offered a new way to synthesize CD-MOFs. Sha et al employed α-CD, KOH, and NaOH to prepare two α-CD-MOFs using the same methodology [64,69]. Using the same procedure, α-CD-MOF-K and β-CD-MOF-K/γ-CD-MOF-K polymers were also prepared by Li and co-workers.…”

Section: Synthetic Strategy Of Cd-mofsmentioning

confidence: 99%

Cyclodextrin-Based Metal-Organic Frameworks (CD-MOFs) in Pharmaceutics and Biomedicine

et al. 2018

View full text Add to dashboard Cite

Metal-organic frameworks (MOFs) show promising application in biomedicine and pharmaceutics owing to their extraordinarily high surface area, tunable pore size, and adjustable internal surface properties. However, MOFs are prepared from non-renewable or toxic materials, which limit their real-world applications. Cyclodextrins (CDs) are a typical natural and biodegradable cyclic oligosaccharide and are primarily used to enhance the aqueous solubility, safety, and bioavailability of drugs by virtue of its low toxicity and highly flexible structure, offering a peculiar ability to form CD/drug inclusions. A sophisticated strategy where CD is deployed as a ligand to form an assembly of cyclodextrin-based MOFs (CD-MOFs) may overcome real-world application drawbacks of MOFs. CD-MOFs incorporate the porous features of MOFs and the encapsulation capability of CD for drug molecules, leading to outstanding properties when compared with traditional hybrid materials. This review focuses on the inclusion technology and drug delivery properties associated with CD-MOFs. In addition, synthetic strategies and currently developed uses of CD-MOFs are highlighted as well. Also, perspectives and future challenges in this rapidly developing research area are discussed.

show abstract

Section: Synthetic Strategy Of Cd-mofsmentioning

confidence: 99%

Cyclodextrin-Based Metal-Organic Frameworks (CD-MOFs) in Pharmaceutics and Biomedicine

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The role of ammonia in the synthesis is not clear. Many of the described alkaline‐based cyclodextrin metal‐organic coordination polymers have been obtained from basic solutions , , , . However there are also examples of alkaline‐based cyclodextrin metal‐organic coordination polymers having been obtained in neutral media , ,…”

Section: Resultsmentioning

confidence: 99%

“…Metal‐organic frameworks (MOFs) formed from cyclodextrins (CDs) and alkali metal ions have been widely described in the literature . The functional properties of CD‐MOFs obtained from γ‐cyclodextrin and alkali metal hydroxides have been studied in detail for a number of applications , .…”

Section: Introductionmentioning

confidence: 99%

Metal‐Organic Coordination Polymers Formed from γ‐Cyclodextrin and Divalent Metal Ions

et al. 2019

View full text Add to dashboard Cite

The chemistry of metal-organic frameworks based on cyclodextrins and alkali metals has been extensively investigated in recent years, but coordination polymers with non-alkali metals have been rarely reported. Here, we describe the synthesis and X-ray crystallographic characterization of a series of coordination polymers, [Ba(H 2 and [Pb(H 2 O)(γ-CD)](NO 3 ) 2 ·11H 2 O (γ-CD-Pb), which were obtained by reacting γ-cyclodextrin with alkaline earth metal ions and [a] Nikolaev

show abstract

“…This allows reducing the amount of nonactive undesirable compounds to be administered at the benefit of an anticipated decrease of toxicity. Numerous active ligands have been proposed to date to produce bioMOFs: peptides (metal peptide frameworks), nucleobases, carbohydrates, porphyrines, as well as some active ingredients . Unfortunately, most of these bioMOFs are still at their initial stages of development and a very few of them have undergone in vivo preclinical evaluation.…”

Section: Toxicity: From In Vitro To In Vivo Evaluationmentioning

confidence: 99%

Nanoparticles of Metal‐Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine

et al. 2018

View full text Add to dashboard Cite

In the past few years, numerous studies have demonstrated the great potential of nano particles of metal-organic frameworks (nanoMOFs) at the preclinical level for biomedical applications. Many of them were reported very recently based on their bioactive composition, anticancer application, or from a general drug delivery/theranostic perspective. In this review, the authors aim at providing a global view of the studies that evaluated MOFs' biomedical applications at the preclinical stage, when in vivo tests are described either for pharmacological applications or for toxicity evaluation. The authors first describe the current surface engineering approaches that are crucial to understand the in vivo behavior of the nanoMOFs. Finally, after a detailed and comprehensive analysis of the in vivo studies reported with MOFs so far, and considering the general evolution of the drug delivery science, the authors suggest new directions for future research in the use of nanoMOFs for biomedical applications.

show abstract

Nontoxic and renewable metal–organic framework based on α-cyclodextrin with efficient drug delivery

Abstract: Two new nontoxic α-CD based compounds were synthesized by different method, which contain different left-handed helix and exhibit efficient drug loading capacity and sustained release behaviors.

Cited by 58 publications

References 24 publications

Cyclodextrin-Based Metal-Organic Frameworks (CD-MOFs) in Pharmaceutics and Biomedicine

Cyclodextrin-Based Metal-Organic Frameworks (CD-MOFs) in Pharmaceutics and Biomedicine

Metal‐Organic Coordination Polymers Formed from γ‐Cyclodextrin and Divalent Metal Ions

Nanoparticles of Metal‐Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine

Contact Info

Product

Resources

About